BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 43.4% in December

BiomX Inc. (NYSEAMERICAN:PHGE) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 78,258 shares, a growth of 43.4% from the November 30th total of 54,560 shares. Based on an average trading volume of 182,170 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.3% of the company’s shares are sold short. Currently, 5.3% of the company’s shares are sold short. Based on an average trading volume of 182,170 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price target on shares of BiomX to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, BiomX presently has an average rating of “Buy” and an average target price of $26.00.

BiomX Stock Performance

Shares of PHGE traded up $0.07 during midday trading on Monday, hitting $2.00. The company had a trading volume of 88,292 shares, compared to its average volume of 92,314. BiomX has a 1 year low of $1.50 and a 1 year high of $22.06. The firm has a market capitalization of $3.06 million, a P/E ratio of -0.08 and a beta of 1.56. The company’s 50-day simple moving average is $5.80 and its 200-day simple moving average is $8.11.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.